Platelet-inhibitor therapy in cardiovascular disease

References

• Fuster V, Chesebro JH. Antithrombotic therapy: role of platelet-inhibitor drugs. 1. Current concepts of thrombogenesis: role of platelets. Mayo Clin Proc 1981: 56(2): 102–12: 2. Pharmacologic effects of platelet-inhibitor drugs. Mayo Clin Proc 1981: 56(2): 185–95
   PubMed Web of Science ®Google Scholar
• Fuster V, Pumphrey CW, McGoon MD, et al. Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10–19 year follow-up. Circulation 1982: 66(2 Pt2): 1157–61
   Google Scholar
• Pumphrey CW, Fuster V, Chesebro JH. Systemic thromboembolism in valvular heart disease and prosthetic heart valves. Mod Concepts Cartlovasc Dis 1982: 51(12): 131–7
   PubMedGoogle Scholar
• Chesebro JH, Fuster V, Elveback LR, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983: 51(9): 1537–41
   PubMed Web of Science ®Google Scholar
• Fuster V, Gersh BJ, Giuliani BR, et al. The natural history of Idiopathic dilated cardiomyopathy. Am J Cardiol 1981: 47(3): 525–31
   PubMed Web of Science ®Google Scholar
• Sullivan JM, Harken DE, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med 1971: 284(25): 1391–4
   PubMed Web of Science ®Google Scholar
• Kasahara T. Clinical effect of dipyridamole Ingestion after prosthetic heart valve replacement—especially on the blood coagulation system. J Jpn Assoc Thorac Surg 1977: 25(8): 1007–21
   Google Scholar
• Groupe de recherche PACTE. Prevention des accidents thromboemboliques systemiquest chez les porteurs de prothesis valvulaires artificielles: essai cooperatif controle du dipyridamole. Coeur 1978: 9: 915–69
   Google Scholar
• Rajah SM, Sreeharan N, Joseph A, et al. A prospective trial of dipyridamole and warfarin In heart valve patients. Acta Therapeutlca 1980: 614 (Suppl 93)
   Google Scholar
• Dale J, Myhxe E, Storstein O, et al. Prevention of arterial thromboembolism with acetyisalicylic acid: a controlled clinical study in patients with aortic bail valves. Am Heart J 1977: 94(1): 101–11
   PubMed Web of Science ®Google Scholar
• Altman R, Boullon F, Rouvier J, et al. Aspirin and prophylaxis of thromboembolic complications In patients with substitute heart valves. J Thorac Cardiovasc Surg 1976: 72(1): 127–9
   PubMed Web of Science ®Google Scholar
• Gould KL. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilatation. 1. Physiologic basis and experimental validation. Am J Cardiol 1978: 41(2): 267–78
   PubMed Web of Science ®Google Scholar
• Steele P, Rainwater J, Vogel R. Platelet suppressant therapy in patients with prosthetic cardiac valves: relationship of clinical effectiveness to alteration of platelet survival time. Circulation 1979: 60(4): 910–3
   PubMed Web of Science ®Google Scholar
• Kempin SJ. Warfarin resistance caused by broccoli. (Letter) N Engl J Med 1983: 308(20): 1229–30
   PubMed Web of Science ®Google Scholar
• Chesebro JH, Fuster V. Thromboembolism in heart valve replacement. In: Kwaan HC, ed. Textbook of thrombosis for clinicians. Philadelphia: WB Saunders, 1982: 146–53
   Google Scholar
• Chesebro JH, Fuster V, Elveback LR, et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984: 310(4): 209–14
   PubMed Web of Science ®Google Scholar
• Campeau L, Enjalbert M, Lesperance J, et al. Atherosclerosis and late closure of aortocoronaiy saphenous vein grafts: sequential angiographic studies at 2 weeks. 1 year, 5 to 7 years, and 10 to 12 years after surgery. Circulation 1983: 68 (3 Pt 2): II 1–7
   Google Scholar
• Cheaebro JH, Fuster V. Platelets and platelet-inhibitor drugs in aortocoronary vein bypass operations. Int J Cardiol 1983: 2(5–6): 511–6
   PubMed Web of Science ®Google Scholar
• Chesebro JH, Clements IP, Fuster V, et al. A platelet-inhibitor-drug trial In coronary-artety bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 1982: 307(2): 73–8
   PubMed Web of Science ®Google Scholar
• Bonchek LI, Boerboom LE, Olinger GN, et al. Prevention of lipid accumulation In experimental vein bypass grafts by antiplatelet therapy. Circulation 1982: 66(2): 338–41
   PubMed Web of Science ®Google Scholar
• Chesebro JH, Fuster V, Nishimura RA, et al. Platelet survival in coronary patients: good response to dipyridamole plus aspirin, partial response to low-dose aspirin with or without dipyridamole: Implications for trials. (Abstr) Circulation 1983: 68(Suppl 3). III 105
   PubMedGoogle Scholar
• Hanson SR, Harker LA, Bjornsson TD. Effects of platelet-modifying drugs on arterial thromboembolism in baboons: aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanisms independent of platelet cyclooxygenase inhibition. J Clin Invest 1985: 75: 1591–9
   PubMed Web of Science ®Google Scholar
• Chesebro JH, Fuster V. Perioperative antiplatelet therapy for aortocoronary artery bypass surgery. Mod Concepts Cardiovasc Dis 1984: 53(12): 65–70
   Google Scholar
• Chesebro JH, Foster V. Drug trials in prevention of occlusion of aorta-coronary artery vein grafts. J Thorac Cardiovasc Surg 1982: 83(1): 90–3
   PubMed Web of Science ®Google Scholar
• Lorenz RL, Weber M, Kotzur J. et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Lancet 1984: 1 (8389): 1261–4
   PubMed Web of Science ®Google Scholar
• Fuster V, Chesebro JH. Pathogenesis of atherosclerosis: the role of platelets and thrombosis. In: Kwann, ed,15 pp 57–81
   Google Scholar
• Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol 1985: 5(6): 175–84B
   Web of Science ®Google Scholar
• Fuster V, Frye RL, Connolly DC, et al. Arteriographic patterns early in the onset of the coronary syndromes. Br Heart J 1975: 37(12): 1250–5
   PubMedGoogle Scholar
• Fuster V, Fass DN, Kaye MP, et al. Arteriosclerosis in normal and von Willebrand pigs: long-term prospective study and aortic transplantation study. Circ Res 1982: 51(5): 587–93
   PubMed Web of Science ®Google Scholar
• Steele PM, Chesebro JH, Fuster V. The natural history of arterial balloon angioplasty in pigs and intervention with platelet-Inhibitor therapy: Implications for clinical trials. (Abstr) Clin Res 1984: 32(2): 209A
   Google Scholar
• Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial: acetyl salicylic add in the secondary prevention of mortality from myocardial Infarction. Br Med J 1974: 1(905): 436–40
   PubMedGoogle Scholar
• The Coronary Drug Project Research Group. Aspirin in coronary heart disease. J Chron Dis 1976: 29: 625–42
   PubMedGoogle Scholar
• Breddin K, Loew D, Lechner K, et al. Secondary prevention of myocardial infarction; comparison of acetyl- salicylic acid, phenprocoumon and placebo: a multicenter two-year prospective study. Thromb Haemost 1979: 41(1): 225–36
   PubMed Web of Science ®Google Scholar
• Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet 1979: 2(8156–7): 1313–5
   PubMed Web of Science ®Google Scholar
• Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin In persons recovered from myocardial Infarction. JAMA 1980: 243(7): 661–9
   PubMed Web of Science ®Google Scholar
• The Persantine-Aspirin Reinfarction Study Research Group. Persantlne and aspirin in coronary heart disease. Circulation 1980: 62(3): 449–61
   Web of Science ®Google Scholar
• The Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 1980: 302(5): 250–6
   PubMed Web of Science ®Google Scholar
• Sulphinpyrazone in post-myocardial infarction: report from the Anturane Reinfarction Italian Study. Lancet 1982: 1 (8266): 237–42
   PubMed Web of Science ®Google Scholar
• Passamani ER. Summary of ongoing clinical trials of platelet-active drugs in cardiovascular disease. Circulation 1980: 62(2 Pt 2): V106–10
   PubMedGoogle Scholar
• Lewis HD Jr. Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N Engl J Med 1983: 309(7): 396–403
   PubMed Web of Science ®Google Scholar
• Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction In intermediate coronary syndrome. Lancet 1981: 1 (8232): 1225–8
   PubMed Web of Science ®Google Scholar
• Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty: natural history of the pathophysiologic response to Injury in a pig model. Circ Res 1985: 57(1): 105–12
   PubMed Web of Science ®Google Scholar